Duopharma Biotech Berhad Dividends and Buybacks
Dividend criteria checks 3/6
Duopharma Biotech Berhad is a dividend paying company with a current yield of 2.24% that is well covered by earnings.
Key information
2.2%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 2.5% |
| Dividend Growth | -6.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | RM 0.028 |
| Payout ratio | 48% |
Recent dividend and buyback updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: DPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: DPHARMA's dividend payments have fallen over the past 10 years.
Dividend Yield vs Market
| Duopharma Biotech Berhad Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (DPHARMA) | 2.2% |
| Market Bottom 25% (MY) | 2.0% |
| Market Top 25% (MY) | 5.2% |
| Industry Average (Pharmaceuticals) | 6.6% |
| Analyst forecast (DPHARMA) (up to 3 years) | 2.5% |
Notable Dividend: DPHARMA's dividend (2.24%) is higher than the bottom 25% of dividend payers in the MY market (2.04%).
High Dividend: DPHARMA's dividend (2.24%) is low compared to the top 25% of dividend payers in the MY market (5.21%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (48%), DPHARMA's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (42%), DPHARMA's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 00:04 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Duopharma Biotech Berhad is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsien Jin Lam | CGS International |
| Kenneth Leong | Malacca Securities Sdn Bhd |
| Norfauzi Bin Nasron | OSK-DMG |